share_log

艾美疫苗：盈利預警

AIM VACCINE: PROFIT WARNING

香港交易所 ·  Mar 3 18:50
Summary by Moomoo AI
艾美疫苗股份有限公司於2024年3月4日發布盈利預警，預計2023年度未經審核淨虧損將介於人民幣18.1億元至19.9億元，較2022年度的淨虧損人民幣2.3億元大幅增加。該公司預期歸屬於母公司擁有人的淨虧損將介於人民幣12.5億元至13.8億元，而2022年度為人民幣3.2億元。增加虧損的主要原因包括對子公司珠海麗凡達生物技術有限公司形成的無形資產及商譽計提減值損失，以及研發費用的大幅增加。公司董事會提醒股東及潛在投資者在交易時需謹慎。
艾美疫苗股份有限公司於2024年3月4日發布盈利預警，預計2023年度未經審核淨虧損將介於人民幣18.1億元至19.9億元，較2022年度的淨虧損人民幣2.3億元大幅增加。該公司預期歸屬於母公司擁有人的淨虧損將介於人民幣12.5億元至13.8億元，而2022年度為人民幣3.2億元。增加虧損的主要原因包括對子公司珠海麗凡達生物技術有限公司形成的無形資產及商譽計提減值損失，以及研發費用的大幅增加。公司董事會提醒股東及潛在投資者在交易時需謹慎。
EME VACCINES CO., LTD. ISSUED A PROFIT WARNING ON MARCH 4, 2024. IT EXPECTS THE UNAUDITED NET LOSS IN 2023 TO BE BETWEEN RMB18.1 BILLION AND $19.9 BILLION, A SIGNIFICANT INCREASE FROM THE NET LOSS OF RMB2.3 BILLION IN 2022. The company expects net losses attributable to its parent owners to range from RMB12.5 billion to $13.8 billion, compared to RMB3.2 billion in 2022. The main reasons for the increase in losses include the loss of intangible assets and goodwill incurred by its subsidiary Zhuhai Livanda Biotechnology Co., Ltd., as well as a significant increase in R&D expenses. The Board of Directors reminds shareholders and potential investors to exercise caution when trading.
EME VACCINES CO., LTD. ISSUED A PROFIT WARNING ON MARCH 4, 2024. IT EXPECTS THE UNAUDITED NET LOSS IN 2023 TO BE BETWEEN RMB18.1 BILLION AND $19.9 BILLION, A SIGNIFICANT INCREASE FROM THE NET LOSS OF RMB2.3 BILLION IN 2022. The company expects net losses attributable to its parent owners to range from RMB12.5 billion to $13.8 billion, compared to RMB3.2 billion in 2022. The main reasons for the increase in losses include the loss of intangible assets and goodwill incurred by its subsidiary Zhuhai Livanda Biotechnology Co., Ltd., as well as a significant increase in R&D expenses. The Board of Directors reminds shareholders and potential investors to exercise caution when trading.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more